Biogen and Ionis Pharmaceuticals have reported encouraging two-year findings from their Phase 2 CELIA clinical study of diranersen, an investigational antisense oligonucleotide designed to reduce the production of tau protein in people with early Alzheimer's disease.
The companies announced the results on November 17, 2026, ahead of and during the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference. The most prominent result was a reported 38% slowing of clinical decline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 96 among participants receiving the 60 mg twice-yearly regimen.
The reported treatment difference was 1.09 points on the CDR-SB scale. Biogen also reported favourable results across several additional measures assessing cognition, daily functioning and disease progression.
The findings are attracting attention because diranersen targets tau production through RNA-based technology rather than attempting to remove amyloid plaques or directly bind extracellular tau proteins. Tau is a major biological feature of Alzheimer's disease and is associated with neuronal dysfunction and disease progression.
However, the results require important scientific context.
The Week 96 findings were generated during an ongoing open-label extension, after the original placebo-controlled period had ended. Participants originally assigned to placebo could have received a single dose of diranersen after entering the extension. In addition, the original Phase 2 study did not meet its primary endpoint assessing dose response at Week 76.
Those limitations do not make the two-year results irrelevant. They do mean that the reported 38% figure should be interpreted as an encouraging clinical signal rather than definitive evidence of treatment efficacy.
Biogen says the findings support further evaluation in a Phase 3 trial designed to confirm the drug's efficacy and safety. Diranersen remains investigational and has not been approved by any regulatory authority.
What Is Diranersen?
Diranersen, also known by its development designation BIIB080 and its earlier Ionis designation IONIS-MAPTRx, is an antisense oligonucleotide (ASO) therapy designed to target the messenger RNA associated with the microtubule-associated protein tau gene, known as MAPT.
The therapy was discovered by Ionis Pharmaceuticals and licensed worldwide to Biogen in December 2019 under an exclusive, royalty-bearing development and commercialisation agreement.
Unlike conventional medicines that bind directly to a protein or its receptor, antisense oligonucleotides are designed to interact with specific RNA sequences. By binding to a target messenger RNA, an ASO can influence the production of the corresponding protein.
In diranersen's case, the target is MAPT mRNA, which provides instructions for producing tau protein.
The intended result is to reduce the production of tau at its source. Biogen says the therapy is designed to reduce all tau isoforms and lower both intracellular and extracellular tau protein.
This mechanism is relevant because abnormal tau accumulation is associated with Alzheimer's pathology. Tau normally performs important functions inside nerve cells, including supporting the structure and stability of microtubules. In Alzheimer's disease, tau can become abnormally modified, aggregate and form intracellular neurofibrillary tangles.
These pathological changes are associated with neuronal dysfunction and cognitive decline.
Diranersen is designed to reduce the amount of tau available for pathological accumulation. It should not, however, be described as a drug that directly removes every existing tau tangle or reverses established neuronal damage.
Reducing the production of a protein and clearing existing pathological deposits are different biological processes.
The distinction also matters when comparing diranersen with monoclonal antibody approaches. Some investigational tau antibodies have focused primarily on extracellular tau species. Diranersen is designed to reduce tau production inside cells, potentially influencing both intracellular and extracellular tau levels.
Whether this upstream mechanism produces a meaningful and durable clinical benefit remains a question for further clinical testing.
CELIA: A Global Phase 2 Study Involving 416 Participants
The CELIA study, registered under ClinicalTrials.gov identifier NCT05399888, is a global, randomised, double-blind, placebo-controlled, dose-ranging Phase 2 trial evaluating diranersen in people with early Alzheimer's disease.
The trial enrolled 416 participants with either mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia.
An important characteristic of the study population was that participants had not previously received anti-amyloid therapy at enrolment. This provides a particular context for interpreting the findings because the results do not establish how diranersen would perform in patients already receiving approved anti-amyloid treatments.
The study involved 138 clinical trial locations and included participants between 50 and 80 years of age.
CELIA evaluated three intrathecal dosing regimens:
- 60 mg administered every six months.
- 115 mg administered every six months.
- 115 mg administered every three months.
Intrathecal administration means that the medicine is delivered into the cerebrospinal fluid through a procedure involving access to the spinal canal.
The original placebo-controlled treatment period was designed to evaluate clinical response, safety and tolerability over 76 weeks. The study's primary endpoint assessed dose response in the change from baseline on the CDR-SB scale at Week 76.
Secondary and exploratory endpoints included additional cognitive and functional measures, as well as cerebrospinal fluid biomarkers and tau positron emission tomography imaging.
Following the placebo-controlled period, participants could enter a long-term open-label extension. The extension allows continued evaluation of safety, tolerability and the durability of treatment effects.
This design is important for understanding the latest announcement. The 96-week findings do not represent a conventional two-year comparison in which one group remained on placebo and another remained on active treatment throughout the entire period.
Instead, the analysis compares participants who continued their assigned diranersen regimen with participants originally assigned to placebo who transitioned into the extension phase.
The Central Result: 38% Slower Decline on CDR-SB at Week 96
The headline finding concerns the Clinical Dementia Rating–Sum of Boxes, a clinical assessment used to evaluate the severity of cognitive and functional impairment in Alzheimer's disease.
The CDR-SB combines information across six areas:
- Memory.
- Orientation.
- Judgment and problem-solving.
- Community affairs.
- Home and hobbies.
- Personal care.
Higher scores generally indicate greater impairment.
At Week 96, Biogen reported that participants receiving the 60 mg diranersen regimen every six months experienced 38% slower clinical decline on CDR-SB compared with participants originally assigned to placebo.
The reported treatment difference was 1.09 points.
The companies also compared the Week 96 result with the earlier Week 76 analysis. The reported relative slowing increased from 26% at Week 76 to 38% at Week 96.
This apparent widening of the treatment difference is one of the main reasons the new results have attracted attention.
However, the interpretation must account for the change in study design between the two time points.
Week 76 was the primary endpoint assessment at the end of the placebo-controlled period. Week 96 was assessed during the ongoing open-label extension.
Consequently, the increase from 26% to 38% should not be interpreted as a direct demonstration that the drug's efficacy necessarily increased under an unchanged randomised placebo-controlled comparison.
The result is promising, but the extension design introduces limitations that Phase 3 research will need to address.
How the Other Cognitive and Functional Measures Performed
Biogen reported results across six clinical scales for the 60 mg twice-yearly regimen.
The reported Week 96 treatment effects were:
Clinical measure| Week 76 reported slowing| Week 96 reported slowing CDR-SB| 26%| 38% ADAS-Cog13| 42%| 54% MMSE| 50%| 38% ADCS-ADL-MCI| 0%| 30% ADCOMS| 23%| 38% Modified iADRS| 30%| 46%
These percentages represent the companies' reported estimates of relative slowing of decline. They do not mean that participants recovered the corresponding percentage of lost cognitive ability.
ADAS-Cog13: Reported 54% Slowing
The Alzheimer's Disease Assessment Scale–Cognitive Subscale, 13-item version, evaluates several aspects of cognitive performance.
These include memory, language, orientation and other mental abilities relevant to everyday functioning.
The reported relative slowing increased from 42% at Week 76 to 54% at Week 96 for the 60 mg regimen.
This result provides additional evidence that the CDR-SB finding was not the only cognitive measure showing a favourable treatment difference.
However, the result should be considered within the broader statistical and study-design limitations of the open-label extension.
ADCS-ADL-MCI: Reported 30% Slowing
The Alzheimer's Disease Cooperative Study Activities of Daily Living scale for people with mild cognitive impairment assesses everyday activities.
Functional measurements matter because Alzheimer's disease affects more than memory. As the condition progresses, patients can experience increasing difficulty performing routine activities independently.
The reported relative slowing on ADCS-ADL-MCI increased from 0% at Week 76 to 30% at Week 96.
The change is potentially encouraging because it suggests that the observed clinical signal may extend beyond cognitive testing to daily functioning.
Nevertheless, the Week 96 finding is not a definitive demonstration that the treatment preserves independence over the long term.
ADCOMS: Reported 38% Slowing
The Alzheimer's Disease Composite Score combines elements from multiple clinical assessments to provide a broader measure of disease progression.
Biogen reported 38% slowing on ADCOMS at Week 96, compared with 23% at Week 76.
The result adds another supportive measure to the overall dataset.
Modified iADRS: Reported 46% Slowing
The integrated Alzheimer's Disease Rating Scale combines cognitive and functional information.
The reported relative slowing increased from 30% at Week 76 to 46% at Week 96.
Because the scale incorporates both cognitive and functional dimensions, its results can help researchers assess whether a treatment signal is visible across different aspects of the disease.
MMSE: Reported 38% Slowing
The Mini-Mental State Examination is a widely used cognitive screening and assessment instrument.
Unlike most of the other measures listed, its reported relative slowing declined from 50% at Week 76 to 38% at Week 96.
This is an important detail.
The results did not improve uniformly across all six measures. Five showed greater reported slowing at Week 96, while MMSE showed a smaller relative effect.
That difference should not be hidden in reporting that describes the results as uniformly strengthening over time.
Why the Week 96 Open-Label Extension Matters
The most important qualification in the latest announcement concerns the study's open-label extension.
During a placebo-controlled clinical trial, participants are randomly assigned to treatment groups, and neither the participants nor relevant investigators know the assigned treatment in a double-blind design.
This approach helps reduce bias and supports more reliable comparisons between active treatment and placebo.
The original CELIA placebo-controlled period ran through the Week 76 assessment.
After that period, participants could transition into the long-term extension, where treatment arrangements changed.
Biogen's Week 96 analysis compared 60 participants who received the 60 mg twice-yearly regimen during the placebo-controlled phase and remained on the same dose through two years with 115 participants originally assigned to placebo.
The original placebo participants entered the extension phase. By Week 96, they had received either no doses or one dose of diranersen after transitioning.
The companies describe this as a placebo-equivalent comparator.
That description is relevant, but it should not be confused with a group that remained on placebo under the original randomised conditions for the entire 96 weeks.
Open-label extensions can provide valuable information about longer-term safety, tolerability and potential durability. They can also help researchers understand how treatment effects evolve beyond the original controlled period.
However, they are generally less suitable than a continued blinded randomised comparison for making definitive claims about efficacy.
Differences in treatment exposure, participant retention, expectations, missing data and other factors can influence the results.
For that reason, the Week 96 findings should be considered supportive evidence requiring confirmation rather than a replacement for the original primary endpoint.
The Earlier Phase 2 Primary Endpoint Failure Cannot Be Ignored
The two-year announcement must be read alongside the earlier CELIA results disclosed in May 2026.
At that time, Biogen and Ionis reported that the Phase 2 study had not met its primary endpoint assessing dose response in CDR-SB at Week 76.
The primary endpoint was designed to determine whether the different tested doses produced the expected dose-response relationship.
The study nevertheless produced favourable biomarker findings and pre-specified analyses of cognitive endpoints, particularly among participants receiving the lowest dose of 60 mg every 24 weeks.
Biogen said the strength of the biomarker and efficacy findings justified moving diranersen towards registrational development.
The company also reported that tau pathology was reduced across the studied dose groups.
The May announcement therefore presented a mixed scientific picture:
- The primary dose-response endpoint was not met.
- Tau biomarkers showed substantial reductions.
- Pre-specified cognitive analyses indicated slowing of decline.
- The lowest dose appeared particularly encouraging.
- The safety profile was generally consistent with earlier research.
The November Week 96 results add further information to that picture.
They do not retroactively convert the failed Week 76 primary endpoint into a successful primary endpoint.
This distinction is essential for investors, researchers and patients evaluating the programme.
A clinical trial can generate promising secondary, exploratory or extension findings even when its primary endpoint is not achieved. Those findings may justify additional research, but they do not carry the same evidentiary weight as a successful confirmatory primary endpoint.
The Non-Linear Dose-Response Question
Another important issue in the CELIA programme is the relationship between dose and clinical outcomes.
The study tested 60 mg every six months, 115 mg every six months and 115 mg every three months.
The lowest tested regimen showed the largest treatment effects in the reported clinical analyses.
This is notable because drug development programmes often expect higher exposure to produce stronger biological or clinical effects up to an appropriate therapeutic range.
But biological systems do not always behave in a simple linear fashion.
Higher doses can sometimes produce diminishing returns, different biological effects or a less favourable safety profile.
In its May announcement, Ionis noted that the highest studied dose had a higher incidence of serious adverse events than the other dose groups.
The company also reported that clinical slowing was particularly evident in the lowest-dose group.
The November announcement continued to identify the 60 mg twice-yearly regimen as having the largest treatment effects at two years.
This does not establish the biological explanation for the apparent dose pattern.
Further research will need to determine whether the 60 mg regimen represents the optimal therapeutic exposure, whether the observed difference is reproducible and how treatment effects relate to the degree of tau reduction.
The Phase 3 programme will be particularly important in resolving those questions.
Tau as a Major Target in Alzheimer's Disease Research
Alzheimer's disease is a complex neurodegenerative condition involving several biological processes.
Two of the most extensively studied pathological features are amyloid-beta accumulation and abnormal tau protein.
Amyloid-beta can accumulate outside neurons and form plaques. Tau pathology involves abnormal accumulation and aggregation of tau within neurons.
Both processes are associated with Alzheimer's disease, but they are not interchangeable.
Approved anti-amyloid therapies have demonstrated that targeting amyloid can slow clinical decline in selected patients with early Alzheimer's disease.
However, the availability of amyloid-directed treatments has not eliminated the need to investigate other disease mechanisms.
Tau is an important target because abnormal tau accumulation is closely associated with the development and spread of neurodegenerative pathology.
Researchers are investigating several approaches to tau treatment, including antibodies, vaccines, small molecules and RNA-targeted therapies.
Diranersen belongs to the RNA-targeted category.
Instead of relying on an antibody to bind a tau protein after it has been produced, the ASO is designed to reduce the production of tau by targeting MAPT messenger RNA.
The approach is conceptually different from therapies that focus primarily on extracellular tau.
It could potentially influence a wider range of tau species because the target is the messenger RNA responsible for producing the protein.
However, biological plausibility does not guarantee clinical success.
A therapy may successfully change a biomarker without producing a sufficiently large or durable improvement in symptoms and daily functioning.
The CELIA findings are important because the programme has reported both biomarker effects and clinical signals. The confirmatory question is whether those effects can be demonstrated reliably in a larger, appropriately controlled Phase 3 study.
How Diranersen Differs from Anti-Amyloid Treatments
The current Alzheimer's treatment landscape includes medicines designed to target amyloid pathology.
One example is lecanemab, marketed as Leqembi, developed by Eisai in collaboration with Biogen.
Lecanemab is an anti-amyloid monoclonal antibody used in eligible patients with early Alzheimer's disease.
Diranersen has a different target and mechanism.
Feature| Diranersen| Lecanemab Main target| MAPT mRNA and tau production| Amyloid-beta Drug type| Antisense oligonucleotide| Monoclonal antibody Administration| Intrathecal injection| Intravenous infusion; other formulations and schedules may vary by jurisdiction Development status| Investigational| Approved in certain markets for eligible patients Main research objective| Reduce tau protein production| Reduce amyloid pathology
The comparison illustrates why tau-targeting research is attracting interest.
Alzheimer's disease involves multiple biological pathways, and researchers are investigating whether treatments directed at different pathological processes could eventually have complementary roles.
However, the CELIA study did not establish that diranersen works better than lecane
Nexuswild welcomes factual corrections. Email contact@nexuswild.com with evidence and the article URL.
